This study evaluated the frequency of and potential risk factors for arthralgias and/or myalgias associated with quinupristin-dalfopristin administration. Of 32 patients who received quinupristin-dalfopristin treatment, at least 15 (47%) developed arthralgias and/or myalgias. Clinicians should be aware of these adverse events associated with quinupristin-dalfopristin, which may occur more frequently than has been previously reported.
|Original language||English (US)|
|Journal||Clinical infectious diseases : an official publication of the Infectious Diseases Society of America|
|State||Published - Feb 15 2001|
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases